Please ensure Javascript is enabled for purposes of website accessibility

What Investors Should Look for With Exelixis, DermTech, and Teladoc Health

By Keith Speights and Brian Orelli, PhD - Updated Jun 28, 2021 at 8:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All three healthcare stocks could have solid growth prospects.

Some healthcare stocks are especially intriguing to investors. Telehealth leader Teladoc Health (TDOC -3.94%), biotech Exelixis (EXEL 0.56%), and skin genomics testing pioneer DermTech (DMTK -28.94%) are three that certainly belong in the category. In this Motley Fool Live video recorded on May 12, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about these three healthcare stocks.

Keith Speights: It looks like our top question is from John B. "Can I get your thesis on," and he lists several stocks. Teladoc Health, which ticker there's TDOC, Exelixis, the ticker there is EXEL. He asks about DermTech, ticker there is DMTK, and GoodRx, ticker there is GDRX. Brian, any thoughts on any of those stocks?

Brian Orelli: Maybe I'll take Exelixis and DermTech and you can get the other two.

Exelixis, I think the thing that you want to look at is its pipeline. It had to restart its pipeline, and all of its drugs are really in early stages. It has in-license quite a few drugs and it's ramping up its discovery efforts again, and so I think that's really where we should be focused. Cabometyx is its only drug on the market. It goes by different names, but it's the same underlying active ingredient. That allows the company to bring in a lot of cash, so that will help them not have to dilute themselves.

On DermTech, the company is developing or has a test for the melanoma skin cancer. I think the biggest thing is doctors tend to be creatures of habit, and this is the new technology, and so they're going to have to spend a lot of time and money to get doctors to actually try the product. They're giving away the product a lot for free. Then the other thing you want to watch there is that the company is able to get the coverage by insurance companies.

Speights: I'm a shareholder of DermTech, I think you are, too, Brian.

Orelli: Yes.

Speights: My thesis for DermTech is when a company has a product that's better, faster, and cheaper than the current standard of care, it's certainly one worth watching, and if you feel inclined to invest in one, it's certainly one that's worth having on your radar screen. I think DermTech has a product that's better, faster, and cheaper than the current biopsy approach for melanoma diagnosis. I like the stock, it's been really volatile.

The stock is down a lot over the last couple of months, but I don't think that's really related to the company itself, I think it's just more market trends of some transition out of high-growth stocks. I like the long-term prospects for DermTech. I don't have a huge position in it, but I think the company, as it gains traction with payers and gets in front of dermatologists more, I think that DermTech could be a big winner over the long run.

Let me talk about Teladoc Health. It's another one in our last minute. I won't be able to get to GoodRx, but we'll try to talk more about GoodRx next week maybe. But Teladoc Health is another stock that I own. It's another stock that's been beaten down a lot. I really like the long-term prospects for virtual care in Telehealth chronic disease management. Teladoc is a leader in those areas. It has the widest range of services. It has over 40% of the Fortune 500 as its customers.

I think Teladoc Health is a great stock to buy at a discount right now. I think the long-term prospects are still very, very good. They're going to be other big players get into this market, but I think Teladoc Health is definitely a stock if you don't own, you might want to check out and really look at its prospects for how it could grow, both in the U.S. and internationally.

Brian Orelli, PhD owns shares of DermTech, Inc. and has the following options: short May 2021 $55 calls on DermTech, Inc. Keith Speights owns shares of DermTech, Inc. and Teladoc Health. The Motley Fool owns shares of and recommends DermTech, Inc. and Teladoc Health. The Motley Fool recommends Exelixis and GoodRx Holdings, Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$37.26 (-3.94%) $-1.53
Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$21.67 (0.56%) $0.12
GoodRx Holdings, Inc. Stock Quote
GoodRx Holdings, Inc.
GDRX
$9.44 (21.69%) $1.68
DermTech, Inc. Stock Quote
DermTech, Inc.
DMTK
$5.99 (-28.94%) $-2.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
379%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.